Literature DB >> 3515840

Malignant histiocytosis (histiocytic sarcoma). A (the?) major cause of the 'midline granuloma syndrome'.

H Laeng, H Gerber, J Mueller.   

Abstract

Five out of eight consecutive cases with initial symptoms of a 'midline granuloma' were identified as malignant histiocytosis (histiocytic sarcoma) which within 5 months to 4 years led to generalization and death. The three remaining cases also fulfilled the morphological criteria of this type of neoplasia, though these patients are still alive 1/2 to 8 years after diagnosis, possibly as a result of local radiotherapy. The age of the individuals ranged from 18 to 71 years and there was a male preponderance of 7:1. The histiocytic nature of the atypical cells was primarily documented by intense activity of NaF-inhibitable non-specific esterase, of acid phosphatase and of beta-glucuronidase as demonstrated in cryostat sections of formaldehyde-saccharose-fixed fresh biopsy specimens and by the detection of alpha-1-antichymotrypsin, alpha-1-antitrypsin, and lysozyme antigens, in that order of constancy (immunohistochemical examination of formaldehyde-fixed paraffin sections, using the avidin-biotin-peroxidase complex method). There was among the reported cases a considerable heterogeneity with regard to these 'markers'. We conclude that malignant histiocytosis is a (the?) major cause of the 'midline granuloma syndrome'.

Entities:  

Mesh:

Year:  1986        PMID: 3515840     DOI: 10.3109/00016488609108616

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  2 in total

1.  Heterogeneous malignant non Hodgkin's lymphomas as a causative disorder in lethal midline granuloma.

Authors:  R H Laeng; H A Gerber; T Schaffner; K H Bürki
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

2.  CT evaluation of polymorphic reticulosis.

Authors:  M M Teng; C Y Chang; W Y Guo; W Y Li; T Chang
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.